Reuters logo
BRIEF-Acadia Pharmaceuticals announces positive top-line results from phase ii study of pimavanserin for alzheimer's disease psychosis
December 20, 2016 / 12:35 PM / a year ago

BRIEF-Acadia Pharmaceuticals announces positive top-line results from phase ii study of pimavanserin for alzheimer's disease psychosis

Dec 20 (Reuters) - Acadia Pharmaceuticals Inc

* Acadia Pharmaceuticals announces positive top-line results from phase ii study of pimavanserin for alzheimer’s disease psychosis

* Pimavanserin met primary endpoint showing a statistically significant reduction in psychosis versus placebo

* Pimavanserin was generally well tolerated Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below